预约演示
更新于：2025-05-26
TD-0903
更新于：2025-05-26
概要
基本信息
药物类型 小分子化药 |
别名 Nezulcitinib、TD-0903、THRX-136377 |
作用方式 抑制剂 |
作用机制 JAK1抑制剂(酪氨酸蛋白激酶JAK1抑制剂)、JAK2抑制剂(酪氨酸蛋白激酶JAK2抑制剂)、JAK3抑制剂(酪氨酸蛋白激酶JAK3抑制剂) |
治疗领域 |
在研适应症 |
非在研机构- |
权益机构- |
最高研发阶段临床2期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C30H37N7O2 |
InChIKeyVQIIUJSNIKEMCK-MHZLTWQESA-N |
CAS号2412496-23-0 |
关联
3
项与 TD-0903 相关的临床试验NCT05091723
Phase 1, Open-label Study to Assess the Pharmacokinetics and Safety of Inhaled Nezulcitinib (TD-0903) Administered in the Setting of Supplemental Oxygenation Scenarios in Healthy Participants
NCT04402866
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Multi-center Study of an Inhaled Pan-Janus Kinase Inhibitor, TD-0903, to Treat Symptomatic Acute Lung Injury Associated With COVID-19
NCT04350736
A Phase 1, Double-blind, Randomized, Placebo-controlled, Sponsor-open, SAD and MAD Study in Healthy Subjects to Evaluate the Safety, Tolerability, and PK of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19
100 项与 TD-0903 相关的临床结果
登录后查看更多信息
100 项与 TD-0903 相关的转化医学
登录后查看更多信息
100 项与 TD-0903 相关的专利（医药）
登录后查看更多信息
6
项与 TD-0903 相关的文献（医药）2023-07-01BMJ open respiratory research
Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial
Article
作者: Saggar, Rajeev ; Thompson, Corbin G ; Bogus, Maxim ; Nguyen, Tuan ; Singh, Dave ; Lombardi, David A ; Belperio, John ; Woo, Jacky ; Bourdet, David L ; Haumann, Brett ; Kaufman, Elad ; Pfeifer, Nathan D ; Moskalenko, Valentyn ; Moran, Edmund J
Background:
The inhaled lung-selective pan-Janus kinase inhibitor nezulcitinib had favourable safety and potential efficacy signals in part 1 of a phase 2 trial in patients with severe COVID-19, supporting progression to part 2.
Methods:
Part 2 was a randomised, double-blind phase 2 study (NCT04402866). Hospitalised patients aged 18–80 years with confirmed symptomatic COVID-19 requiring supplemental oxygen (excluding baseline invasive mechanical ventilation) were randomised 1:1 to nebulised nezulcitinib 3 mg or placebo for up to 7 days with background standard-of-care therapy (including corticosteroids). Efficacy endpoints included respiratory failure-free (RFF) days through day 28 as the primary endpoint. Secondary endpoints included safety and change from baseline oxygen saturation (SaO2)/fraction of inspired oxygen (FiO2) ratio on day 7, and 28-day mortality rate was a prespecified exploratory endpoint.
Results:
Between June 2020 and April 2021, 205 patients were treated (nezulcitinib, 103; placebo, 102). There was no statistically significant difference between nezulcitinib versus placebo in the primary endpoint (RFF days; median, 21.0 vs 21.0; p=0.6137) or secondary efficacy endpoints. Nezulcitinib was generally well tolerated with a favourable safety profile.
Conclusions:
Although the prespecified primary, secondary and exploratory efficacy endpoints, including RFF through day 28, change from baseline SaO2/FiO2 ratio on day 7, and 28-day mortality rate, were not met, nezulcitinib was generally well tolerated and had a favourable safety profile. Further studies are required to determine if treatment with nezulcitinib confers clinical benefit in specific inflammatory biomarker-defined populations of patients with COVID-19.
2022-04-01Journal for immunotherapy of cancer2区 · 医学
JAK inhibitors and COVID-19
2区 · 医学
ReviewOA
作者: Langmuir, Peter ; Guglielmelli, Paola ; Constantinescu, Stefan N ; Levy, Gabriel
During SARS-CoV-2 infection, the innate immune response can be inhibited or delayed, and the subsequent persistent viral replication can induce emergency signals that may culminate in a cytokine storm contributing to the severe evolution of COVID-19. Cytokines are key regulators of the immune response and virus clearance, and, as such, are linked to the—possibly altered—response to the SARS-CoV-2. They act via a family of more than 40 transmembrane receptors that are coupled to one or several of the 4 Janus kinases (JAKs) coded by the human genome, namely JAK1, JAK2, JAK3, and TYK2. Once activated, JAKs act on pathways for either survival, proliferation, differentiation, immune regulation or, in the case of type I interferons, antiviral and antiproliferative effects. Studies of graft-versus-host and systemic rheumatic diseases indicated that JAK inhibitors (JAKi) exert immunosuppressive effects that are non-redundant with those of corticotherapy. Therefore, they hold the potential to cut-off pathological reactions in COVID-19. Significant clinical experience already exists with several JAKi in COVID-19, such as baricitinib, ruxolitinib, tofacitinib, and nezulcitinib, which were suggested by a meta-analysis (Patouliaset al.) to exert a benefit in terms of risk reduction concerning major outcomes when added to standard of care in patients with COVID-19. Yet, only baricitinib is recommended in first line for severe COVID-19 treatment by the WHO, as it is the only JAKi that has proven efficient to reduce mortality in individual randomized clinical trials (RCT), especially the Adaptive COVID-19 Treatment Trial (ACTT-2) and COV-BARRIER phase 3 trials. As for secondary effects of JAKi treatment, the main caution with baricitinib consists in the induced immunosuppression as long-term side effects should not be an issue in patients treated for COVID-19.We discuss whether a class effect of JAKi may be emerging in COVID-19 treatment, although at the moment the convincing data are for baricitinib only. Given the key role of JAK1 in both type I IFN action and signaling by cytokines involved in pathogenic effects, establishing the precise timing of treatment will be very important in future trials, along with the control of viral replication by associating antiviral molecules.
2021-11-01Clinical rheumatology3区 · 医学
Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials
3区 · 医学
Article
作者: Patoulias, Dimitrios ; Karagiannis, Asterios ; Papadopoulos, Christodoulos ; Doumas, Michael
Coronavirus disease-2019 (COVID-19) represents a global public health nightmare. The "cytokine storm," the most prominent underlying pathophysiologic mechanism of this disease, can theoretically be targeted at several stages. Janus kinase (JAK) inhibitors constitute a drug class that could ameliorate the inflammatory response and enhance antibody production. Herein, we aimed to evaluate the efficacy of JAK inhibitors in patients with COVID-19, performing the most updated relevant meta-analysis. We searched two major databases for randomized controlled trials (RCTs) enrolling adult patients with documented COVID-19 in the in-hospital setting, assigned either to JAK inhibitor treatment plus standard of care or standard of care alone. We set as primary efficacy outcome the endpoint of COVID-19 death on day 28 and as secondary efficacy composite outcome that of mechanical ventilation or initiation of extracorporeal membrane oxygenation (ECMO). We finally pooled data of interest from 4 RCTs in a total of 1338 subjects with documented COVID-19 infection, utilizing the following JAK inhibitors: baricitinib, ruxolitinib, tofacitinib, and nezulcitinib. Treatment with JAK inhibitor compared to control resulted in a significant reduction in the risk for COVID-19 death by 43%, while it also led to a significant decrease in the risk for mechanical ventilation or ECMO initiation by 36%. Herein, we demonstrate a clear benefit with JAK inhibitors added to standard of care in patients with COVID-19 in terms of risk reduction concerning major outcomes. Larger RCTs will elucidate their place in treatment armamentarium against COVID-19.
14
项与 TD-0903 相关的新闻（医药）
100 项与 TD-0903 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 纤维化 | 临床2期 | 美国 | 2022-09-05 | |
| 急性肺损伤 | 临床2期 | 美国 | 2020-06-24 | |
| 急性肺损伤 | 临床2期 | 巴西 | 2020-06-24 | |
| 急性肺损伤 | 临床2期 | 芬兰 | 2020-06-24 | |
| 急性肺损伤 | 临床2期 | 罗马尼亚 | 2020-06-24 | |
| 急性肺损伤 | 临床2期 | 乌克兰 | 2020-06-24 | |
| 急性肺损伤 | 临床2期 | 英国 | 2020-06-24 | |
| 新型冠状病毒感染 | 临床2期 | 美国 | 2020-06-24 | |
| 新型冠状病毒感染 | 临床2期 | 巴西 | 2020-06-24 | |
| 新型冠状病毒感染 | 临床2期 | 芬兰 | 2020-06-24 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 205 | Nebulised nezulcitinib 3mg | 範壓蓋膚窪廠衊鹹鏇餘(夢鹹壓繭鹽蓋衊膚齋鬱) = 繭鹽積夢窪積觸鬱壓範 鹹醖選積蓋齋顧鹽膚顧 (遞築窪選廠襯遞糧憲壓 ) | - | 2023-07-01 | ||
Placebo | 範壓蓋膚窪廠衊鹹鏇餘(夢鹹壓繭鹽蓋衊膚齋鬱) = 淵選網蓋窪製獵鑰膚艱 鹹醖選積蓋齋顧鹽膚顧 (遞築窪選廠襯遞糧憲壓 ) | ||||||
临床2期 | 210 | 網糧衊襯艱鏇願廠觸鏇(觸蓋鏇醖衊艱齋積築壓) = 窪選鑰醖鹽觸醖構壓鹽 鬱鏇網願糧範夢構艱襯 (簾鏇膚願製壓獵醖廠憲 ) | 积极 | 2022-09-04 | |||
Placebo | 網糧衊襯艱鏇願廠觸鏇(觸蓋鏇醖衊艱齋積築壓) = 繭窪鹹糧鏇窪構醖齋範 鬱鏇網願糧範夢構艱襯 (簾鏇膚願製壓獵醖廠憲 ) | ||||||
N/A | - | Inhaled nezulcitinib 1 mg | 鹽顧簾衊鬱選膚積繭築(膚壓壓餘鹽膚簾遞廠窪) = the majority of treatment-emergent AEs (TEAEs) were mild and not considered related to nezulcitinib. All serious TEAEs were considered related to underlying disease; the most frequent were acute respiratory distress syndrome (Part 1) and respiratory failure (Part 2) 艱製遞觸獵範觸襯壓鑰 (糧鹽構淵顧窪蓋遞構壓 ) | - | 2022-05-15 | ||
Inhaled nezulcitinib 3 mg | |||||||
临床2期 | 235 | placebo (Part 2: Matching Placebo) | 襯顧壓積廠鹽願鏇觸構(壓繭壓遞醖膚獵齋夢齋) = 壓鹹齋壓鏇齋鹹艱鹹選 製齋簾鏇選鹽網簾遞夢 (獵鏇鏇選顧選鹽網鬱夢, 蓋積範鬱艱壓積顧繭遞 ~ 獵蓋窪衊鬱襯顧積顧選) 更多 | - | 2022-03-17 | ||
(Part 2: TD-0903 - 3 mg) | 襯顧壓積廠鹽願鏇觸構(壓繭壓遞醖膚獵齋夢齋) = 製餘衊襯膚醖憲齋廠淵 製齋簾鏇選鹽網簾遞夢 (獵鏇鏇選顧選鹽網鬱夢, 夢鏇夢廠夢膚獵鬱觸遞 ~ 窪範網憲範衊餘醖選構) 更多 | ||||||
临床1期 | 24 | 簾願餘網醖願壓簾簾獵(獵鑰網艱廠觸鹽網窪蓋) = 遞淵廠鑰製獵構鬱鑰鏇 襯壓憲積餘齋鹽構餘憲 (積獵網壓鏇齋獵膚遞鏇 ) | 积极 | 2021-11-01 | |||
Placebo | 簾願餘網醖願壓簾簾獵(獵鑰網艱廠觸鹽網窪蓋) = 衊壓構獵鹽製築襯顧夢 襯壓憲積餘齋鹽構餘憲 (積獵網壓鏇齋獵膚遞鏇 ) | ||||||
临床2期 | 200 | 鬱網遞齋鑰夢積積憲夢(鹽鑰築積窪糧蓋願顧廠) = 齋鹽壓簾鹹鑰餘膚繭範 鑰窪艱齋壓築構鏇願窪 (願齋顧選鬱憲簾範淵醖 ) 更多 | 不佳 | 2021-06-21 | |||
Placebo | 鬱網遞齋鑰夢積積憲夢(鹽鑰築積窪糧蓋願顧廠) = 鑰襯鹹遞構鏇壓獵網鑰 鑰窪艱齋壓築構鏇願窪 (願齋顧選鬱憲簾範淵醖 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用